Common questions about Fampyra (FAQ)
Q: How quickly do people usually start to see effects from Fampyra?
A: Regulatory guidelines state that the initial trial period for this medicine typically lasts two to four weeks. During this time, a healthcare professional assesses the patient to determine if a measured improvement in walking ability is achieved. Continuation of treatment is restricted only to those who demonstrate a benefit during this initial assessment period.
Q: What should I do if I forget to take a dose of Fampyra?
A: Official administration guidelines strictly instruct against taking a double or extra dose to make up for one that was missed. If a dose is missed, official guidelines state that the next dose should be taken at the regularly scheduled time.
Q: Can Fampyra affect my ability to drive or operate machinery?
A: Regulatory documents indicate that this medicine may affect your ability to drive or operate complex machinery. This is due to common adverse reactions, such as dizziness, balance disorder, and fatigue. Patients are advised to understand how the medicine affects them before engaging in these activities.
Q: Does Fampyra treat all types of multiple sclerosis?
A: Fampyra is officially indicated for the improvement of walking in adults living with Multiple Sclerosis (MS). Clinical trial data reviewed by regulatory agencies showed that the increase in measured response was observed across the major clinical courses of MS, including Relapsing-Remitting, Secondary Progressive, and Primary Progressive types.
Q: Do older adults use Fampyra differently than younger adults?
A: Official information notes that the use of Fampyra in older adults requires caution. This is primarily because age-related changes can affect kidney function, which is responsible for eliminating the drug from the body. Therefore, careful monitoring of renal function is specifically emphasized prior to and during treatment in this population.
Q: Is Fampyra considered a disease-modifying therapy for MS?
A: Fampyra is officially classified as a symptomatic therapy. This means its purpose is to address a specific symptom associated with MS, which is walking disability. It is not considered a disease-modifying therapy (DMT), which typically works to alter the course of the disease itself.
Q: What kind of monitoring is done while a person is on Fampyra?
A: Official guidelines require that a healthcare professional assess the patient's renal function (kidney function) before initiating treatment and that this be monitored regularly during therapy. The healthcare professional will also evaluate the patient's walking ability and assess the risk factors for seizures before prescribing this medicine.
Q: Are there any specific foods or drinks I need to avoid while taking Fampyra?
A: The primary regulatory documents do not list any specific foods or drinks that must be avoided due to an interaction with Fampyra. The focus of the product information is on drug-drug interactions, particularly those involving the Organic Cation Transporter 2 (OCT2) pathway.
Q: What are the most commonly reported mild side effects of Fampyra?
A: According to regulatory data from clinical studies, the most common adverse reaction reported is urinary tract infection (UTI), which affected more than 1 in 10 people. Other reactions commonly reported by less than 1 in 10 people include dizziness, headache, trouble sleeping (insomnia), and nausea.
Q: Is it normal to feel dizzy or lightheaded when starting Fampyra?
A: Official product information lists dizziness as a common adverse reaction, meaning it was reported by less than 1 in 10 people in clinical trials. This is a recognized potential effect of the medicine.
Q: Can Fampyra be taken with vitamins or dietary supplements?
A: Official product information focuses primarily on interactions with certain prescription medicines, specifically those known as Organic Cation Transporter 2 (OCT2) inhibitors. The primary regulatory documents do not provide specific warnings or instructions regarding most vitamins or common dietary supplements.
Q: Is Fampyra approved for use in children with MS?
A: Fampyra is strictly indicated only for use in adult patients aged 18 years and older. Its use is not recommended for children or adolescents because its safety and effectiveness have not been established in these younger age groups.
Q: Does Fampyra have any effect on fatigue related to MS?
A: Fampyra is officially indicated only for the improvement of walking disability. While some research evidence has explored the drug's effect on fatigue scores, its use is not officially based on outcomes related to fatigue.
Q: Are there specific symptoms that mean Fampyra is working?
A: Official guidelines for assessing benefit rely on objective measurements of walking speed performed by a healthcare professional, such as the Timed 25-Foot Walk. Continuation of the medicine is restricted to those who demonstrate this measured benefit during the initial treatment period.
Q: Can men and women expect different outcomes from using Fampyra?
A: Official analyses of the core clinical trials indicated that the treatment response observed was independent of demographic characteristics, including gender.
Q: What are the most common reasons patients stop taking Fampyra?
A: Official guidelines mandate that treatment be discontinued if a patient does not demonstrate a measured improvement in walking ability during the initial assessment period. Additionally, the drug must be permanently discontinued if a patient experiences a serious adverse reaction, such as a seizure or a severe allergic reaction.
Q: Can Fampyra be taken if a person has a bladder infection?
A: Urinary tract infection (UTI) is the most common adverse reaction reported in clinical studies. Official guidelines state that if signs of a UTI occur, a healthcare professional must be notified.
Q: Are there official guidelines on what to do if side effects occur?
A: Official guidance is specific for serious adverse reactions. If a seizure or a severe allergic reaction occurs, regulatory documents require that the medicine be permanently discontinued.
Q: How long does the effect of one dose of Fampyra last?
A: Fampyra is designed as a prolonged-release tablet to ensure a steady amount of the medicine in the body. Its elimination from the body is typically measured by a half-life ( t1/2) of approximately 5 to 7 hours in people with normal kidney function.
Q: Can Fampyra cause difficulty sleeping (insomnia)?
A: According to official product information, difficulty sleeping (insomnia) is listed as a common adverse reaction. Common reactions are those reported by less than 1 in 10 people in clinical trials.
Q: How long can someone safely take Fampyra?
A: The foundational evidence for the drug comes from short-term controlled clinical trials, typically lasting 9 to 14 weeks. Longer-term data has been gathered from observational settings for up to two years. There is no specified regulatory limit on the duration of treatment, but continuation is subject to periodic assessment of sustained benefit.
Q: What official guidelines are there for Fampyra use during breastfeeding?
A: Fampyra is not recommended for use during breastfeeding. This is because it is currently unknown whether the medicine is excreted into human milk, and there is a documented potential for serious adverse reactions to occur in a breast-fed infant.
